Effects of intermittent theta-burst transcranial magnetic stimulation on cognition and hippocampal volumes in bipolar depression.

"Disclosure statement IJT has received consulting fees from Lundbeck Canada, Sumitomo Dainippon, and Community Living British Columbia. AM has served on an advisory board for Allergan Canada. FVR receives research support from CIHR, Brain Canada, Michael Smith Foundation for Health Research, Vancouver Coastal Health Research Institute, and Weston Brain Institute for investigator-initiated research. Philanthropic support from Seedlings Foundation. In-kind equipment support for this investigator-initiated trial from MagVenture. He has received honoraria for participation in an advisory board for Janssen. RWL has received funds for speaking/consulting or research from: Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Healthy Minds Canada, Janssen, Lundbeck, Lundbeck Institute, Michael Smith Foundation for Health Research, MITACS, Myriad Neuroscience, Ontario Brain Institute, Otsuka, Unity Health, Vancouver Coastal Health Research Institute, Viatris, and VGH-UBCH Foundation. LNY is a consultant and/or has received speaker fees and/or sits on the advisory board and/or receives research funding from Abbvie, Alkermes, Allergan, Canadian Network for Mood and Anxiety Treatments (CANMAT), Canadian Institutes of Health Research (CIHR), Dainippon Sumitomo Pharma, Gedeon Richter, Intracellular Therapies, Lundbeck, Merck, Otsuka, Sanofi and Sunovion over the past three years. All other authors have no conflicts to declare."

"The data for this secondary analysis was collected as a part of the iTBS trial for bipolar depression (McGirr et al. ), conducted in accordance with IFCN recommendations (Rossini et al. ). The study was conducted across two Canadian centres (University of British Columbia [UBC], British Columbia, and University of Calgary [UofC], Alberta) and the data collection spanned from October 2016 to March 2020. The original trial was registered with clinicaltrials.gov (NCT02749006) and was approved by UBC Clinical Research Ethics Board of the University of British Columbia and Conjoint Health Ethical Review Board of UofC. Written informed consent was obtained from all participants."